Salatino A et al. observed that chemoresistant ovarian cancer patients may be characterized by higher ferritin heavy chain levels than chemosensitive patients, and overexpression of ferritin heavy chain significantly eliminated cisplatin-mediated ROS, subsequently leading to reduced responsiveness in ovarian cancer cells [179]. This evidence concerns the gene SLC3A2 and ovarian carcinoma.